Article
Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer.
EMBO molecular medicine - 1 Apr 2018
Yan Yuqian, An Jian, Yang Yinhui, Wu Di, Bai Yang, Cao William, Ma Linlin, Chen Junhui, Yu Zhendong, He Yundong, Jin Xin, Pan Yunqian, Ma Tao, Wang Shangqian, Hou Xiaonan, Weroha Saravut John, Karnes R Jeffrey, Zhang Jun, Westendorf Jennifer J, Wang Liguo, Chen Yu, Xu Wanhai, Zhu Runzhi, Wang Dejie, Huang Haojie
Abstract excerpt
AKT-mTOR and androgen receptor (AR) signaling pathways are aberrantly activated in prostate cancer due to frequent PTEN deletions or SPOP mutations. A clinical barrier is that targeting one of them often activates the other. Here, we demonstrate that HDAC3 augments AKT phosphorylation in prostate cancer cells and its overexpression correlates with AKT phosphorylation in patient samples. HDAC3 facilitates...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.